查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087726

治療性疫苗市場：2026-2032年全球市場預測（依疫苗類型、技術平台、給藥途徑、療法和應用分類）

Therapeutic Vaccines Market by Vaccine Type, Technology Platform, Route of Administration, Therapy Type, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，治療性疫苗市場將成長至 795.7 億美元，複合年成長率為 12.29%。

主要市場統計數據
基準年 2025 353.4億美元
預計年份：2026年 396.2億美元
預測年份 2032 795.7億美元
複合年成長率 (%) 12.29%

治療性疫苗正從一種小眾免疫療法概念轉變為精準醫療的策略性支柱。與預防感染的預防性疫苗不同，治療性疫苗旨在訓練或重新誘導免疫系統對已確立的疾病標靶（例如腫瘤抗原、持續性病毒感染和免疫介導性疾病）的攻擊作用。

癌症免疫療法、mRNA平台、病毒載體、樹突細胞療法、胜肽疫苗、溶瘤策略和個人化新抗原發現等技術的融合正在塑造這個市場。美國食品藥物管理局（FDA）批准的SiplEthel-T用於治療轉移性去勢抗性前列腺癌，以及卡介苗（BCG）用於治療非肌肉浸潤性膀胱癌等，都表明，當患者選擇、抗原選擇和生產品質得到妥善匹配時，治療性免疫活化可以帶來臨床價值。根據國際癌症研究機構（IARC）的數據，2022年全球新患者約2000萬例，因此，對持續有效的標靶治療性疫苗的臨床需求仍然非常高。

治療性疫苗領域的變革性變化

治療性疫苗的格局正從標準化抗原產品轉向個人化免疫療法。隨著腫瘤定序、生物資訊學和快速生產技術能夠比十年前更有效地整合到臨床工作流程中，針對患者特異性新抗原的個人化癌症疫苗正蓬勃發展。

人工智慧（AI）的累積影響

人工智慧 (AI) 正成為治療性疫苗整個價值鏈中極具影響力的驅動力。 AI 模型可輔助抗原發現、新抗原優先排序、HLA 結合預測、免疫反應建模、患者分層以及臨床試驗中心最佳化。這些能力在個人化癌症疫苗領域尤其關鍵，因為速度和準確性決定了療法是否能在臨床有意義的時間範圍內生產和交付。

區域層面關於全球治療性疫苗部署的關鍵見解

隨著中國、日本、韓國、印度和澳洲加大對癌症研究、生技藥品生產、基因組醫學和臨床試驗體系的投資，亞太地區正在迅速發展。中國已成為全球癌症臨床試驗的重要中心，而日本則在再生醫學和先進醫療領域擁有完善的系統流程。韓國正在擴大生物製藥和細胞療法的生產規模，印度則擁有龐大的患者群體和疫苗生產的專業知識。澳洲也憑藉其強大的研究網路和國際認可的臨床試驗標準，為早期臨床開發提供支援。

主要團體對治療性疫苗策略的看法

在東協市場，癌症負擔日益加重、醫院網路不斷完善、基因組分析能力不斷提升，以及新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國在生物技術領域的投資，都凸顯了治療性疫苗臨床試驗的重要性。在海灣合作理事會（GCC）國家，先進療法、基因組醫學、癌症治療基礎設施以及醫療衛生系統的現代化，都使這些領域成為優先事項，從而催生了對結合臨床專業知識和本地能力建設的夥伴關係的需求。

來自影響治療性疫苗需求的關鍵國家的見解

美國憑藉其領先的腫瘤中心、美國國立衛生研究院（NIH）支持的免疫學研究、美國食品藥物管理局（FDA）在免疫療法方面的豐富經驗、高密度的臨床試驗以及由創業投資支持的強大的食品藥物管理局生態系統，在治療性疫苗創新領域處於領先地位。加拿大擁有強大的轉化研究能力、公共衛生能力和學術癌症網路。同時，墨西哥和巴西在拉丁美洲的臨床試驗多樣性、癌症治療准入計畫、疫苗生產諮詢以及區域醫療保健系統夥伴關係發揮著日益重要的作用。

為治療性疫苗領域的領導者提供的實用建議

行業領導者應優先考慮選擇檢驗的抗原、基於生物標記的患者招募以及聯合治療策略，以應對免疫定序。開發個人化治療性疫苗的機構應儘早投資於定序合作、生物資訊檢驗、閉合迴路生產、品管、可追溯性系統以及能夠按時交付患者特定產品的物流系統。

治療性疫苗分析的調查方法

本執行摘要基於二手資訊來源，資料來源包括經檢驗的公開資料，例如監管出版刊物、同行評審的生物醫學文獻、全球健康資料集、臨床試驗註冊庫、腫瘤學指南以及國家衛生機構資料。尤其著重於來自美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、世界衛生組織 (WHO)、國際癌症研究機構 (IARC)、美國國立衛生研究院 (NIH)、ClinicalTrials.gov 以及經認可的公共衛生和生物醫學研究資訊來源的證據。

結論：治療性疫苗的策略性展望

隨著免疫學、基因組學、人工智慧和先進製造技術的融合，治療性疫苗正進入一個關鍵階段。儘管該領域仍面臨抗原選擇、腫瘤異質性、免疫抑制、試驗設計、生產複雜性和保險報銷等挑戰，但其科學基礎比以往任何時候都更加堅實。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 治療性疫苗市場：依疫苗類型分類

  • 癌症治療疫苗
  • 用於治療感染疾病的疫苗
  • 用於治療自體免疫疾病的疫苗

第8章 治療性疫苗市場：依技術平台分類

  • 細胞衍生疫苗
  • 核酸疫苗
  • 基於載體的疫苗
  • 胜肽類和蛋白質類疫苗

第9章 治療性疫苗市場：依給藥途徑分類

  • 皮內注射
  • 皮下
  • 肌肉內部

第10章 治療性疫苗市場：依治療類型分類

  • 單藥治療
  • 聯合治療

第11章 治療性疫苗市場：依應用領域分類

  • 腫瘤學
  • 感染疾病
  • 自體免疫疾病
  • 神經病變

第12章 治療性疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 治療性疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 治療性疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Agenus Inc.
  • Argos Therapeutics, Inc.
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • BioNTech SE
  • Celldex Therapeutics, Inc.
  • CSL Limited
  • CureVac NV
  • Dynavax Technologies Corporation
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Heat Biologics, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Northwest Biotherapeutics, Inc.
  • Novartis AG
  • Nykode Therapeutics ASA
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Transgene SA
  • Vaccinogen, Inc.
  • VBI Vaccines Inc.
Product Code: MRR-030298DFF753

The Therapeutic Vaccines Market is projected to grow by USD 79.57 billion at a CAGR of 12.29% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 35.34 billion
Estimated Year [2026] USD 39.62 billion
Forecast Year [2032] USD 79.57 billion
CAGR (%) 12.29%

Therapeutic vaccines are moving from a niche immunotherapy concept into a strategic pillar of precision medicine. Unlike prophylactic vaccines that prevent infection, therapeutic vaccines are designed to train or redirect the immune system against established disease targets, including tumor antigens, persistent viral infections, and immune-mediated disorders.

The market is being shaped by the convergence of cancer immunotherapy, mRNA platforms, viral vectors, dendritic-cell approaches, peptide vaccines, oncolytic strategies, and personalized neoantigen discovery. FDA-approved examples such as sipuleucel-T for metastatic castration-resistant prostate cancer and BCG use in non-muscle-invasive bladder cancer demonstrate that therapeutic immune activation can deliver clinical value when patient selection, antigen choice, and manufacturing quality align. With the International Agency for Research on Cancer reporting about 20 million new cancer cases globally in 2022, the clinical need for durable, targeted therapeutic vaccines remains significant.

Transformative Shifts in the Therapeutic Vaccine Landscape

The therapeutic vaccines landscape is shifting from standardized antigen products toward individualized immunotherapies. Personalized cancer vaccines that target patient-specific neoantigens are gaining momentum because tumor sequencing, bioinformatics, and rapid manufacturing can now be integrated into clinical workflows more effectively than a decade ago.

At the same time, the success of mRNA vaccine infrastructure has accelerated interest in mRNA therapeutic vaccines for oncology and infectious diseases. Combination strategies are also transforming development models, particularly pairing therapeutic vaccines with immune checkpoint inhibitors, cytokines, targeted therapies, or adjuvants to overcome tumor immune evasion and improve response durability. Regulatory expectations are also evolving toward stronger translational evidence, standardized potency assays, and clearer immune correlates, improving development discipline across therapeutic vaccine pipelines.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a high-impact enabler across the therapeutic vaccine value chain. AI models support antigen discovery, neoantigen ranking, HLA-binding prediction, immune-response modeling, patient stratification, and trial-site optimization. These capabilities are especially important in personalized cancer vaccines, where speed and accuracy determine whether a therapy can be manufactured and delivered within a clinically meaningful window.

The cumulative impact is a faster, more data-driven development process, but the benefits depend on validated datasets, transparent model governance, reproducible algorithms, and regulatory-grade evidence. Industry leaders are increasingly using AI to reduce wet-lab screening burden, improve biomarker selection, identify resistance mechanisms, and design adaptive trials while maintaining human scientific oversight and data privacy safeguards.

Key Regional Insights Across Global Therapeutic Vaccine Adoption

Asia-Pacific is expanding rapidly as China, Japan, South Korea, India, and Australia invest in oncology research, biologics manufacturing, genomic medicine, and clinical trial capacity. China has become an important global site for oncology trials, Japan maintains structured pathways for regenerative and advanced therapies, South Korea is scaling biologics and cell-therapy manufacturing, India offers a large patient base and vaccine production expertise, and Australia supports early-phase clinical development through strong research networks and internationally recognized trial standards.

North America remains a leading region because the United States combines NIH-backed immunology research, FDA experience with cancer immunotherapies, advanced genomic sequencing capacity, venture financing, and deep clinical trial infrastructure, while Canada contributes academic cancer centers, public health research, and translational immunology programs. Europe benefits from the European Medicines Agency, Horizon Europe research funding, national cancer missions, and strong oncology clusters in Germany, France, Italy, Spain, and the United Kingdom, supporting therapeutic cancer vaccine research and advanced therapy regulation.

Latin America, led by Brazil and Mexico, is strengthening clinical trial participation, oncology care access, and vaccine implementation capabilities, although reimbursement variability and infrastructure gaps continue to shape adoption speed. The Middle East is building precision medicine capacity through GCC health investments, national genomics initiatives, and cancer care modernization. Africa is increasingly relevant for infectious disease vaccine research, implementation science, clinical trial inclusion, and regional manufacturing initiatives aligned with public health security and equitable access.

Key Group Insights for Therapeutic Vaccine Strategy

ASEAN markets are becoming more relevant for therapeutic vaccine trials because of growing cancer burden, improving hospital networks, expanding genomic capabilities, and regional biotechnology investment in countries such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries are prioritizing advanced therapeutics, genomic medicine, cancer care infrastructure, and health-system modernization, creating demand for partnerships that combine clinical expertise with local capacity building.

The European Union provides a harmonized regulatory and research environment for advanced therapy development through EMA coordination, cross-border clinical research, data protection frameworks, and research funding that supports immuno-oncology, mRNA platforms, and personalized medicine. BRICS economies add scale through large patient populations, domestic biomanufacturing, national immunization expertise, and public-sector health priorities, making them important for both clinical development and access strategy.

G7 countries continue to lead in innovation funding, regulatory science, intellectual property generation, genomic research, and high-complexity clinical trial execution. NATO-aligned markets add resilience considerations, including secure supply chains, biologics manufacturing continuity, cold-chain reliability, health security preparedness, and coordinated responses to emerging infectious disease threats that can influence therapeutic vaccine platform readiness.

Key Country Insights Shaping Therapeutic Vaccine Demand

The United States leads therapeutic vaccine innovation through major oncology centers, NIH-supported immunology research, FDA experience with immunotherapies, high clinical trial density, and a deep venture-backed biotechnology ecosystem. Canada contributes strong translational research, population health capabilities, and academic cancer networks, while Mexico and Brazil are increasingly important for clinical trial diversity, oncology access programs, vaccine manufacturing discussions, and regional health-system partnerships across Latin America.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support therapeutic vaccine development through cancer research networks, academic hospitals, national genomics programs, and EMA-aligned regulatory pathways that encourage evidence-based clinical development. Germany and France add strong biomanufacturing and immunology capabilities, Italy and Spain contribute oncology trial networks and hospital-based research, and the United Kingdom remains influential in genomics, adaptive trial design, and immuno-oncology research. Russia maintains scientific capabilities in immunology, virology, and vaccine research, though international collaboration conditions can affect development pathways.

In Asia-Pacific, China is scaling oncology research, clinical trial activity, mRNA development, and domestic biomanufacturing; India combines vaccine manufacturing scale with rising cancer care demand and expanding clinical research capacity; Japan offers advanced regulatory experience, strong academic hospitals, and established oncology care infrastructure; South Korea is a global biologics manufacturing hub with growing immunotherapy research; and Australia remains a preferred destination for early-phase clinical trials, immuno-oncology studies, and research collaborations supported by high-quality clinical governance.

Actionable Recommendations for Therapeutic Vaccine Leaders

Industry leaders should prioritize validated antigen selection, biomarker-defined patient enrollment, and combination therapy strategies that address immune escape. Organizations developing personalized therapeutic vaccines should invest early in sequencing partnerships, bioinformatics validation, closed-loop manufacturing, quality control, chain-of-identity systems, and logistics capable of delivering patient-specific products on schedule.

Commercial success will also depend on evidence generation beyond response rates, including overall survival, progression-free survival, durability of immune response, safety, cost-effectiveness, patient-reported outcomes, and real-world evidence. Partnerships with academic cancer centers, contract development and manufacturing organizations, diagnostic providers, health systems, and regulators can reduce execution risk and accelerate market readiness while ensuring compliance with evolving standards for advanced immunotherapies.

Research Methodology for Therapeutic Vaccine Analysis

This executive summary is based on secondary research from verified public sources, including regulatory agency publications, peer-reviewed biomedical literature, global health datasets, clinical trial registries, oncology guidelines, and national health agency materials. Priority was given to evidence from FDA, EMA, WHO, IARC, NIH, ClinicalTrials.gov, and recognized public health and biomedical research sources.

The analysis applied cross-validation across disease burden, clinical development activity, technology trends, regulatory pathways, immune-oncology evidence, manufacturing readiness, and regional health-system capacity. Market interpretation emphasizes evidence-backed signals rather than speculative revenue claims, with particular attention to oncology, chronic infectious diseases, mRNA platforms, personalized medicine, AI-enabled discovery, biomarker strategies, and real-world implementation considerations.

Conclusion: Strategic Outlook for Therapeutic Vaccines

Therapeutic vaccines are entering a decisive phase as immunology, genomics, AI, and advanced manufacturing converge. While the field still faces challenges in antigen selection, tumor heterogeneity, immune suppression, trial design, manufacturing complexity, and reimbursement, the scientific foundation is stronger than ever.

Organizations that combine clinical rigor with scalable platforms, companion diagnostics, validated biomarkers, and regional partnership strategies will be best positioned to advance durable patient benefit. The next wave of therapeutic vaccine leadership will likely be defined by precision, speed, safety, manufacturing reliability, regulatory evidence quality, and measurable improvement in clinical outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Therapeutic Vaccines Market, by Vaccine Type

  • 7.1. Cancer Therapeutic Vaccines
  • 7.2. Infectious Disease Therapeutic Vaccines
  • 7.3. Autoimmune Disease Therapeutic Vaccines

8. Therapeutic Vaccines Market, by Technology Platform

  • 8.1. Cell-Based Vaccines
  • 8.2. Nucleic Acid-Based Vaccines
  • 8.3. Vector-Based Vaccines
  • 8.4. Peptide & Protein-Based Vaccines

9. Therapeutic Vaccines Market, by Route of Administration

  • 9.1. Intradermal
  • 9.2. Subcutaneous
  • 9.3. Intramuscular

10. Therapeutic Vaccines Market, by Therapy Type

  • 10.1. Monotherapy
  • 10.2. Combination Therapy

11. Therapeutic Vaccines Market, by Application

  • 11.1. Oncology
  • 11.2. Infectious Diseases
  • 11.3. Autoimmune Disorders
  • 11.4. Neurological Disorders

12. Therapeutic Vaccines Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Therapeutic Vaccines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Therapeutic Vaccines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Agenus Inc.
  • 16.2. Argos Therapeutics, Inc.
  • 16.3. AstraZeneca plc
  • 16.4. Bavarian Nordic A/S
  • 16.5. BioNTech SE
  • 16.6. Celldex Therapeutics, Inc.
  • 16.7. CSL Limited
  • 16.8. CureVac N.V.
  • 16.9. Dynavax Technologies Corporation
  • 16.10. Gilead Sciences, Inc.
  • 16.11. GlaxoSmithKline plc
  • 16.12. Heat Biologics, Inc.
  • 16.13. Inovio Pharmaceuticals, Inc.
  • 16.14. Johnson & Johnson
  • 16.15. Merck & Co., Inc.
  • 16.16. Moderna, Inc.
  • 16.17. Northwest Biotherapeutics, Inc.
  • 16.18. Novartis AG
  • 16.19. Nykode Therapeutics ASA
  • 16.20. Pfizer Inc.
  • 16.21. Sanofi S.A.
  • 16.22. Takeda Pharmaceutical Company Limited
  • 16.23. Transgene S.A.
  • 16.24. Vaccinogen, Inc.
  • 16.25. VBI Vaccines Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL THERAPEUTIC VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL THERAPEUTIC VACCINES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL THERAPEUTIC VACCINES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL THERAPEUTIC VACCINES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL-BASED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL-BASED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL-BASED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID-BASED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID-BASED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID-BASED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VECTOR-BASED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VECTOR-BASED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VECTOR-BASED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE & PROTEIN-BASED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE & PROTEIN-BASED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE & PROTEIN-BASED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. GCC THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. GCC THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. GCC THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 102. GCC THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. GCC THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. G7 THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. G7 THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. G7 THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 120. G7 THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. G7 THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. NATO THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. NATO THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NATO THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 126. NATO THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. NATO THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. CANADA THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 139. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. MEXICO THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 145. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 151. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. GERMANY THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 163. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. FRANCE THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 169. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 175. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ITALY THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 181. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. SPAIN THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 187. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. INDIA THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 199. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. JAPAN THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 205. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 211. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 217. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)